Dr. Sato

Takami Sato, MD, PhD

Contact Dr. Sato

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
  2. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
  3. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy
  4. Toxicities after radioembolization with yttrium-90 SIR-spheres: Incidence and contributing risk factors at a single center
  5. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: A pilot study
  6. Side-branch embolization before90Y radioembolization: Rate of recanalization and new collateral development
  7. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine
  8. Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments?
  9. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma
  10. Locoregional Management of Hepatic Metastasis From Primary Uveal Melanoma
  11. Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: Are there safe and potentially effective treatments?
  12. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: Immunoadhesins for human IL-10 with therapeutic potential
  13. High-dose immunoembolization: Survival benefit in patients with hepatic metastases from uveal melanoma
  14. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
  15. Genomic typing of uveal melanoma: Reply
  16. The biology and management of uveal melanoma
  17. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor
  18. Locoregional Treatment of Malignant Hepatic Tumors with Biologic Response Modifiers
  19. Role of cytogenetics in management of uveal melanoma
  20. A pilot study of low-dose thalidomide and interferon α-2b in patients with metastatic melanoma who failed prior treatment
  21. Calculation of survival of patients with stage III melanoma [1]
  22. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: Results of a phase II study
  23. Immunopharmacological analysis of an autologous, hapten-modified human melanoma vaccine
  24. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine
  25. Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: A new approach to cancer immunotherapy